Data support advancement of GS-6791 into clinical testing in patients with inflammatory diseases; first-in-human Phase 1 trial in healthy ...

A nonbiologic oral IL-23 inhibitor is more effective and safer than an approved oral JAK inhibitor for moderate-to-severe ...

Tiziana Life Sciences, Ltd. (Nasdaq: TLSA) (“Tiziana” or the “Company”), today announces it will advance its second asset, a fully human anti-IL-6 receptor (“IL-6R”) monoclonal antibody, TZLS-501.

Greek yogurt supplementation post-training significantly reduces inflammation markers in young males, offering insights into ...

Neuroinflammation is linked to a host of detrimental brain disorders, including Alzheimer's and Parkinson's disease. A ...

The latest announcement is out from Tiziana Life Sciences ( (TLSA) ).

Icotrokinra demonstrated superior skin clearance at Weeks 16 and 24 compared to deucravacitinib and similar adverse event ...

Coya's COYA 303 showed strong immune modulation and reduced inflammation in the brain, supporting its development for ...

Icotrokinra is a first-in-class oral peptide drug that selectively inhibits the IL-23 receptor, disrupting IL-23 signaling ...

Neuroinflammation is linked to a host of detrimental brain disorders, including Alzheimer's and Parkinson's disease.

Tiziana Life Sciences (TLSA) will advance its second asset, a fully human anti-IL-6 receptor monoclonal antibody, TZLS-501. Tiziana will pursue ...

Maintaining weight loss with regular exercise rather than the glucagon-like peptide-1 receptor agonist (GLP-1RA) liraglutide, ...